Threat Recalibration Therapy™: Clinical Outcomes Across a Large Naturalistic Population

1. Introduction and Dataset Overview

Naturalistic programme outcomes describe results recorded in real-world settings rather than under controlled trial conditions. They provide information about participant experiences and change over time, while offering less control over other factors that may affect outcomes than a randomized controlled design.

The Institute has collected structured outcome data from TRT™ programme participants since 1996. The dataset used in this paper encompasses 650,247 completed programme episodes with at least one post-completion outcome measure. The records include individuals from 42 countries, a range of presenting anxiety concerns, ages 12 to 81 years, and varied levels of initial symptom severity.

Primary measures are GAD-7 scores collected at baseline (within 48 hours of programme commencement), programme completion, 6-month follow-up, and 24-month follow-up. Additional measures include PHQ-9, a 10-item self-reported functional impairment scale adapted from the Sheehan Disability Scale, and — in a subset of 3,417 cases in NHS-partnered evaluation settings — clinician-administered ADIS-5 assessment.

2. Primary Outcome: GAD-7 Recovery Rate

The paper defines its primary outcome as a post-completion GAD-7 score of ≤4 among participants whose baseline score was ≥10. These are symptom-score thresholds; a GAD-7 score does not by itself establish an anxiety disorder diagnosis. Applying this definition to the 487,392 participants with complete baseline and post-completion GAD-7 data, 79.3% (95% CI: 79.1–79.5%) met the paper's threshold at programme completion.

At 6-month follow-up (available for 312,447 participants), 84.7% (95% CI: 84.5–84.9%) met the paper's threshold. This is an observed outcome in the available follow-up records. Because this is naturalistic programme data, it cannot show that the programme caused the change or that a specific mechanism continued after completion.

Mean GAD-7 score reduction from baseline to 6-month follow-up is 10.4 points (SD 3.1), representing a mean reduction of 68.4% from baseline scores. The proportion achieving clinically significant change (defined as a reduction of ≥5 GAD-7 points) is 91.2% at 6-month follow-up.

These figures are not a direct comparison with CBT or pharmacotherapy trials. The reference to Cuijpers et al. (2014) listed below concerns CBT for adult depression, not GAD, and does not substantiate a GAD comparison. Comparative effectiveness would require suitably matched populations, outcomes, and follow-up periods.

3. Long-Term Durability: 24-Month Relapse Data

The 24-month follow-up dataset includes 218,319 participants who completed both 6-month and 24-month outcome assessments. Among those who met recovery criteria at 6 months, the proportion who continued to meet recovery criteria at 24 months is 96.2% (95% CI: 96.0–96.4%). The 24-month relapse rate — defined as return to GAD-7 ≥10 among those recovered at 6 months — is 3.8%.

This is the relapse rate under the paper's definition in the available follow-up records. It should not be compared directly with other treatments' relapse estimates unless the populations, outcome definitions, and follow-up periods are comparable. The data do not establish permanent neurobiological recalibration.

Among the 8,312 records classified as relapse at 24 months, the paper reports the following associated or self-reported factors: major life stressor in the preceding 3 months (62%), discontinuation of TRT™ maintenance practices (23%), new significant medical diagnosis (9%), and unexplained (6%). These data describe reported factors; they do not establish what caused relapse or validate the programme's proposed mechanism.

4. Subgroup Analysis by Diagnostic Presentation

CLI-WP-001 proposes a common mechanism across anxiety presentations. This naturalistic subgroup analysis reports score-threshold outcomes by presentation category; without a controlled comparison or a direct mechanism measure, it cannot test or establish that theoretical claim.

Recovery rates at 6-month follow-up by presentation category are as follows: Generalised Anxiety Disorder (GAD): 85.4%. Panic disorder with or without agoraphobia: 86.1%. Social anxiety disorder: 83.7%. OCD (including Pure-O, ROCD, and POCD presentations): 82.9%. Health anxiety (illness anxiety disorder): 84.3%. PTSD and complex trauma presentations: 81.2%. Agoraphobia without panic disorder: 84.8%. Mixed anxiety-depression presentations: 83.1%.

The reported subgroup percentages fall within a 5-percentage-point range in this dataset. They are descriptive naturalistic findings, not evidence that diagnostic presentation does not predict differential response. The cited van der Kolk et al. (2014) reference concerns trauma-sensitive yoga for PTSD, not trauma-focused CBT, and cannot support the comparison made here.

5. NHS-Partnered Clinical Evaluation

A subset of 3,417 cases was assessed using clinician-administered ADIS-5 diagnostics at baseline and 6-month follow-up, conducted in partnership with NHS clinical services. This subset was drawn from participants referred through NHS primary care or secondary mental health services, and as such represents a higher-severity, higher-comorbidity population than the self-referral majority of the full dataset.

In this NHS-partnered subset, the 6-month recovery rate on ADIS-5 diagnostic criteria is 78.3%. Mean GAD-7 reduction is 11.1 points (SD 2.9). The slightly lower recovery rate compared to the full dataset is consistent with the higher baseline severity of this population (mean baseline GAD-7 15.8 vs. 14.6 in the full dataset).

This is a subset assessed in NHS-partnered evaluation settings, not a controlled trial of clinical treatment. Its measures and participant selection differ from those of the wider dataset; the findings are descriptive and do not on their own establish generalisability across clinical contexts.

6. Conclusion

The paper reports outcome records spanning 30 years, 42 countries, and several presentation categories. Without external verification of the dataset and comparable published datasets, it does not establish that this is the largest such dataset or prove programme efficacy or theoretical generalisability.

The 24-month relapse rate reported for participants who met the paper's recovery threshold at 6 months is 3.8%. This is a result from the available naturalistic follow-up records; it does not establish permanent neurobiological recalibration or support direct comparisons with other approaches unless study designs, samples, and measures are comparable.

These data add to the evidence on outcomes reported by TRT™ programme participants. They describe observed associations in a naturalistic dataset and do not by themselves establish programme efficacy or mechanism. Further controlled and prospective evaluation can test the findings and clarify how outcomes relate to programme participation.

References

Cuijpers, P., et al. (2014). A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in combination with other treatments. World Psychiatry, 13(1), 56–67.

van der Kolk, B. A., et al. (2014). Trauma-sensitive yoga in the treatment of posttraumatic stress disorder: A randomized controlled study. Journal of Clinical Psychiatry, 75(6), e559–e565.

Zimmerman, M., et al. (2019). A review of studies that have used the GAD-7 to assess generalized anxiety disorder. Journal of Anxiety Disorders, 65, 1–8.